Study of Ruxolitinib Cream in Children With Atopic Dermatitis

Summary

This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in pediatric participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.

Timeline

Start

2021-12-16

Primary completion

2023-08-07

Completion

2023-08-07

Publications

• Stein Gold L, Bissonnette R, Forman S, Zaenglein A, Kuo Y, Angel B, Chen X, Kallender H, Paller AS. A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis. Am J Clin Dermatol. 2025 Mar;26(2):275-289. doi: 10.1007/s40257-024-00909-5. Epub 2025 Jan 6.

Drugs

Indications